Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 3/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.63 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015473 | 0.95 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638103 | 0.90 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11222112 | 0.88 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL67131 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL26981114 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1532103 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11008256 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL14037129 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19631092 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL4906617 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | claimed |
| JP-4603265-B2 | — | — | 2010-12-22 | — | — | JP | claimed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | claimed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | claimed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | claimed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | claimed |
| EP-2678349-B1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| EP-2678349-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012115256-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | WO | disclosed |
| CN-101289483-B | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG | 2012-06-20 | — | — | CN | disclosed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | ADORA2A 4653/4885ADORA1 3267/4885ADORA2B 4756/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | ADORA2A 4741/4885ADORA1 4768/4885ADORA2B 4601/4885 |
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | ADORA2A 4404/4885ADORA1 3037/4885ADORA2B 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.